Lantern Pharma Shares Clinical Update From Ongoing Phase 2 HARMONIC Clinical Trial For Never Smokers With Advanced NSCLC, Including An 86% Clinical Benefit Rate In The Initial Patient Cohort
Portfolio Pulse from Benzinga Newsdesk
Lantern Pharma (NASDAQ:LTRN) announced positive preliminary results from its Phase 2 HARMONIC clinical trial for never smokers with advanced NSCLC. The trial showed an 86% clinical benefit rate in the initial patient cohort, with no additional safety concerns. LP-300, combined with chemotherapy, demonstrated promising efficacy regardless of prior TKI treatments.
August 05, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lantern Pharma's Phase 2 HARMONIC trial for never smokers with advanced NSCLC showed an 86% clinical benefit rate in the initial patient cohort. The trial demonstrated promising efficacy and no additional safety concerns, which could positively impact LTRN's stock price.
The positive preliminary results from the Phase 2 HARMONIC trial, including an 86% clinical benefit rate and no additional safety concerns, are likely to boost investor confidence in Lantern Pharma. This could lead to a short-term increase in LTRN's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100